Zoetis Stock News

Zoetis (NYSE:ZTS) is scheduled to announce Q4 earnings results on Tuesday, February 15th, before market open.The consensus EPS Estimate is $0.96 (+5.5% Y/Y) and the consensus…

Mairs & Power Inc. lowered its position in Zoetis Inc. by 54.5% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,617 shares…

Zoetis (ZTS) is set to report earnings and revenue figures and provide updates on its pipeline when it releases fourth-quarter 2021 results.

Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Amazon.com, Inc. (AMZN), and Tesla, Inc. (TSLA).

Zoetis (NYSE:ZTS) declares $0.325/share quarterly dividend, in line with previous.Forward yield 0.65%Payable June 1; for shareholders of record April 21; ex-div April 20.See ZTS Dividend

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #dividend--Zoetis has declared a dividend of $0.325 per share for the second quarter of 2022.

Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mednax (MD) purchases Night Lite Pediatrics, LLC in Orlando to enhance its pediatric business line.

The FDA approves Sanofi's (SNY) Enjaymo for the treatment of hemolysis in adult patients with cold agglutinin disease. Enjaymo is the first therapy to be approved for this indication.

NEW YORK, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Zoe , a digital wealth platform leader in connecting clients with leading financial advisors, is pleased to introduce one of their new Advisor Network partners. After a lengthy vetting process designed to ensure they provide top-of-the-line financial planning and investment management with a client-first mindset, Zoe is pleased to announce that Pure Financial Advisors was accepted as a registered independent advisory firm (RIA) partner. Pure Financial Advisors, ranked among RIA Channel''s Top 100 ETF Power Users and Advisory HQ''s Top 12 San Diego Financial Advisors & RIAs , was founded in 2007 by Michael Fenison. His goal was to create positive change in the financial industry by building a financial planning firm that emphasized tax planning and an institutional approach to investing. Importantly, Pure Financial was designed to be free from all conflicts of interest, and to act as fiduciaries, always placing their clients'' interests above their own.

Zoetis Inc. found using ticker (ZTS) now have 12 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 264 and 220 with the average target price sitting at 246.33. Given that the stocks previous close was at 200.92 this would imply there is a potential upside of 22.6%. The 50 day moving average now sits at 219.35 and the 200 day MA is 201.79. The market capitalisation for the company is $94,408m. Visit the company website at: https://www.zoetis.com [stock_market_widget type="chart" symbol="ZTS" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] The potential market cap would be $115,745m based on the market concensus. Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

General Motors Co., Tesla Inc., Marvell Technology Inc., FedEx Corp. and Zoetis Inc are highlighted in this Analyst Blog article.

We have narrowed our search to five U.S. corporate giants (market capital > $50 billion) that are currently trading on the dip. These are: TSLA, GM, FDX, MRVL and ZTS.

We have narrowed our search to five U.S. corporate giants (market capital > $50 billion) that are currently trading on the dip. These are: TSLA, GM, FDX, MRVL and ZTS.